医学
结直肠癌
前瞻性队列研究
入射(几何)
癌症
静脉血栓栓塞
结直肠外科
静脉血栓形成
腹部外科
肺栓塞
外科
深静脉
置信区间
回顾性队列研究
低分子肝素
内科学
血栓形成
物理
光学
作者
Eun-Young Lee,Sung Bum Kang,Sang Il Choi,Eun Ju Chun,Min Jeong Kim,Duck Woo Kim,Heung‐Kwon Oh,Myong Hoon Ihn,Jin Won Kim,Soo Mee Bang,Jeong-Ok Lee,Yu Jung Kim,Jee Hyun Kim,Jong Seok Lee,Moon Hyoung Lee
出处
期刊:Cancer Research and Treatment
[Korean Cancer Association]
日期:2016-07-15
卷期号:48 (3): 978-989
被引量:16
摘要
Pharmacologic thromboprophylaxis is routinely recommended for Western cancer patients undergoing major surgery for prevention of venous thromboembolism (VTE). However, it is uncertainwhetherroutine administration of pharmacologic thromboprophylaxis is necessary in all Asian surgical cancer patients. This prospective study was conducted to examine the incidence of and risk factors for postoperative VTE in Korean colorectal cancer (CRC) patients undergoing major abdominal surgery.This study comprised two cohorts, and none of patients received perioperative pharmacologic thromboprophylaxis. In cohort A (n=400), patients were routinely screened for VTE using lower-extremity Doppler ultrasonography (DUS) on postoperative days 5-14. In cohort B (n=148), routine DUS was not performed, and imaging was only performed when there were symptoms or signs that were suspicious for VTE. The primary endpoint was the VTE incidence at 4 weeks postoperatively in cohort A.The postoperative incidence of VTE was 3.0% (n=12) in cohort A. Among the 12 patients, eight had distal calf vein thromboses and one had symptomatic thrombosis. Age ≥ 70 years (odds ratio [OR], 5.61), ≥ 2 comorbidities (OR, 13.42), and white blood cell counts of > 10,000/μL (OR, 17.43) were independent risk factors for postoperative VTE (p < 0.05). In cohort B, there was one case of VTE (0.7%).The postoperative incidence of VTE, which included asymptomatic cases, was 3.0% in Korean CRC patients who did not receive pharmacologic thromboprophylaxis. Perioperative pharmacologic thromboprophylaxis should be administered to Asian CRC patients on a risk-stratified basis.
科研通智能强力驱动
Strongly Powered by AbleSci AI